Vir Biotechnology, Inc. (VIR)
Data as of , from SEC Form 4 filings.
See up to 3 months of VIR. The 7-day demo opens the 1M and 3M ranges and puts VIR on your watchlist.
Start 7-day demoLatest VIR insider trades
Janet Napolitano - DirectorOpen-market sale$30K- Brent Sabatini - Officer
About Vir Biotechnology, Inc. (VIR)
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
- SAN FRANCISCO, CA
- 367
- 2019
- XNAS
VIR Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Other acquisition / disposition | 2 | 16,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
VIR insider transactions (Form 4)
4861 Form 4 filings on record, the earliest from Oct 24, 2024, newest first. Filing history page 2 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 191,854 | $5.98 footnote F2 | $1.15M | |
| ||||||
 Vicki L. Sato - Director | Open-market sale | Common Stock | 22,000 | $6.00 footnote F2 | $132K | |
| ||||||
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 127,938 | $6.39 footnote F2 | $818K | |
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 61,493 | $6.44 footnote F4 | $396K | |
| ||||||
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 227,803 | $6.15 footnote F2 | $1.40M | |
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 235,971 | $6.38 footnote F4 | $1.51M | |
| ||||||
| Jason O'Byrne - Officer | Open-market sale | Common Stock | 6,799 | $5.56 | $38K | |
| Verneuil Vanina de - Officer | Open-market sale | Common Stock | 2,385 | $5.16 | $12K | |
| Verneuil Vanina de - Officer | Open-market sale | Common Stock | 1,365 | $5.86 | $8K | |
| Vicki L. Sato - Director | Open-market sale | Common Stock | 22,000 | $5.64 footnote F2 | $124K | |
| ||||||
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 24,453 | $6.50 footnote F2 | $159K | |
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 100 | $6.49 | $649 | |
| ||||||
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 66,403 | $6.05 footnote F4 | $402K | |
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 46,696 | $5.96 footnote F2 | $278K | |
| ||||||
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 144,266 | $6.15 footnote F2 | $888K | |
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 154,383 | $5.99 footnote F4 | $925K | |
| ||||||
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 220,535 | $6.20 footnote F2 | $1.37M | |
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 109,675 | $6.30 footnote F4 | $691K | |
| ||||||
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 16,671 | $6.07 footnote F2 | $101K | |
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 12,844 | $6.10 footnote F4 | $78K | |
| ||||||
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 249,060 | $6.14 footnote F2 | $1.53M | |
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 2,300 | $6.08 footnote F4 | $14K | |
| ||||||
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 72,133 | $5.60 footnote F2 | $404K | |
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 466,242 | $6.05 footnote F4 | $2.82M | |
| ||||||
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 450,342 | $5.56 footnote F2 | $2.50M | |
| SVF Endurance (Cayman) Ltd - 10% Owner | Open-market sale | Common Stock | 73,955 | $5.69 footnote F4 | $421K | |
| ||||||
| Vicki L. Sato - Director | Open-market sale | Common Stock | 22,000 | $5.84 footnote F2 | $128K | |
| ||||||
| Vicki L. Sato - Director | Open-market sale | Common Stock | 22,000 | $4.99 | $110K | |
| Vicki L. Sato - Director | Open-market sale | Common Stock | 22,000 | $4.99 | $110K | |
| Mark Eisner - Officer | Open-market sale | Common Stock | 6,796 | $5.47 | $37K | |
| Mark Eisner - Officer | Open-market sale | Common Stock | 3,586 | $5.47 | $20K | |
| Vicki L. Sato - Director | Open-market sale | Common Stock | 22,000 | $5.10 | $112K | |
| Robert J. More - Director | Other | Common Stock | 14,027 | $0.00 | - | |
| Robert J. More - Director | Other | Common Stock | 14,027 | $0.00 | - | |
 Norbert W. Bischofberger - Director | Other | Common Stock | 10,667 | $0.00 | - | |
| Norbert W. Bischofberger - Director | Other | Common Stock | 10,667 | $0.00 | - | |
| Robert J. More - Director | Grant or award | Common Stock | 8,000 | $0.00 | - | |
| Robert J. More - Director | Grant or award | Stock Option (Right to Buy) | 16,000 | $0.00 | - | |
| Vicki L. Sato - Director | Grant or award | Common Stock | 8,000 | $0.00 | - | |
| Vicki L. Sato - Director | Grant or award | Stock Option (Right to Buy) | 16,000 | $0.00 | - | |
| Norbert W. Bischofberger - Director | Grant or award | Common Stock | 8,000 | $0.00 | - | |
| Norbert W. Bischofberger - Director | Grant or award | Stock Option (Right to Buy) | 16,000 | $0.00 | - | |
| Verneuil Vanina de - Officer | Open-market sale | Common Stock | 76 | $8.22 | $625 | |
| Jason O'Byrne - Officer | Grant or award | Common Stock | 75,000 | $0.00 | - | |
| Jason O'Byrne - Officer | Grant or award | Stock Option (Right to Buy) | 150,000 | $0.00 | - | |
| Verneuil Vanina de - Officer | Open-market sale | Common Stock | 4,397 | $10.11 | $44K | |
| Verneuil Vanina de - Officer | Open-market sale | Common Stock | 1,403 | $7.20 | $10K | |
| Verneuil Vanina de - Officer | Open-market sale | Common Stock | 2,347 | $9.47 | $22K | |
Item 8.01, 9.01
Item 5.02, 7.01, 9.01
Item 2.02, 9.01
Item 5.02
Recent VIR Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| O'Byrne Jason | Former Officer | 19,357 | $213K | View on EDGAR | |
| O'Byrne Jason | Former Officer | 28,333 |
VIR insider trading FAQ
What is the latest insider trade for VIR?
Vir Biotechnology, Inc. (VIR) had 1 insider filing in the last 90 days, with the most recent on 2026-08-12. The full record for VIR runs to 61 Form 4 filings, the earliest from 2024-10-24. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying VIR stock?
No insider purchases of VIR were filed in the last 90 days.
How many insiders are selling VIR stock?
No insider sales of VIR were filed in the last 90 days. 60 sales are on record for this company.
Where can I see VIR SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects VIR Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Robert J. More view on EDGAR
- - Timothy Coughlin view on EDGAR
- - Janet Napolitano view on EDGAR
- - Brent Sabatini view on EDGAR
- - Charles Elliott Sigal view on EDGAR
- - Janet Napolitano view on EDGAR
- - Robert J. More view on EDGAR
- - Jeffrey S. Hatfield view on EDGAR
- - Ramy Farid view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where VIR's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow VIR with a 7-day demo
- VIR on your watchlist
- Every VIR Form 4 filing on record
- Up to 3 months of VIR price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
